TY - JOUR
T1 - Current status of inhaled nitric oxide therapy for lung transplantation in Japan
T2 - a nationwide survey
AU - Yoshiyasu, Nobuyuki
AU - Sato, Masaaki
AU - Nakajima, Daisuke
AU - Tomioka, Yasuaki
AU - Watanabe, Yui
AU - Shiraishi, Takeshi
AU - Funaki, Soichiro
AU - Maeda, Sumiko
AU - Tomoshige, Koichi
AU - Nakajima, Takahiro
AU - Tsuchiya, Tomoshi
AU - Sugimoto, Seiichiro
AU - Yoshino, Ichiro
AU - Nagayasu, Takeshi
AU - Chida, Masayuki
AU - Minami, Masato
AU - Okada, Yoshinori
AU - Toyooka, Shinichi
AU - Date, Hiroshi
AU - Nakajima, Jun
N1 - Funding Information:
YW received a consultancy fee from COSMOSWEB Co., Ltd.; ST received honoraria from TAIHO PHARMACEUTICAL Co., Ltd., Boehringer Ingelheim Co., Ltd., Chugai Pharmaceutical Co., Ltd.; ST also received research grants from TAIHO PHARMACEUTICAL Co., Ltd., Astellas Pharma Inc., Eisai Co., Ltd. The others have no conflict of interest.
Funding Information:
We are sincerely grateful to AIR WATER INC., an appointed overseas manufacturer and seller of pharmaceutical INOflo DS?, who provided the photographs displayed in Fig. 1 , and to Sanyu Technologies Ltd., who manufactured the industrial NO gas supply system. We thank Edanz Group (https://en-author-services.edanz.com/ac ) for editing the final draft of this manuscript.
Publisher Copyright:
© 2021, The Japanese Association for Thoracic Surgery.
PY - 2021/10
Y1 - 2021/10
N2 - Objectives: Currently, inhaled nitric oxide (NO) therapy for lung transplantation is not covered by public health insurance in Japan. In this study, we evaluated the perioperative use and safety of inhaled NO therapy for lung transplantation. Methods: Data regarding the duration of treatment and adverse events of inhaled NO therapy were collected for all lung transplantations performed from January 1, 2015, to December 31, 2019, at nine lung transplant facilities in Japan. Results: During the study period, lung transplants were performed in 357 patients, among whom inhaled NO therapy was administered to 349 patients (98%). The median initial and median maximum inhaled NO doses were 10 and 20 ppm, respectively. Inhaled NO therapy was introduced during surgery and continued postoperatively in 313 patients (90%) for a median of 4 days. Significant improvements in oxygenation and decreases in pulmonary arterial pressure were observed in patients receiving inhaled NO therapy. Side effects of inhaled NO therapy, such as methemoglobinemia, were observed in 15 patients (4%), with a significant incidence in patients aged < 18 years. Conclusions: Inhaled NO therapy was performed in almost all patients who underwent lung transplantation in Japan and showed reasonable efficacy. Therefore, public health insurance coverage for inhaled NO therapy during lung transplantation is recommended.
AB - Objectives: Currently, inhaled nitric oxide (NO) therapy for lung transplantation is not covered by public health insurance in Japan. In this study, we evaluated the perioperative use and safety of inhaled NO therapy for lung transplantation. Methods: Data regarding the duration of treatment and adverse events of inhaled NO therapy were collected for all lung transplantations performed from January 1, 2015, to December 31, 2019, at nine lung transplant facilities in Japan. Results: During the study period, lung transplants were performed in 357 patients, among whom inhaled NO therapy was administered to 349 patients (98%). The median initial and median maximum inhaled NO doses were 10 and 20 ppm, respectively. Inhaled NO therapy was introduced during surgery and continued postoperatively in 313 patients (90%) for a median of 4 days. Significant improvements in oxygenation and decreases in pulmonary arterial pressure were observed in patients receiving inhaled NO therapy. Side effects of inhaled NO therapy, such as methemoglobinemia, were observed in 15 patients (4%), with a significant incidence in patients aged < 18 years. Conclusions: Inhaled NO therapy was performed in almost all patients who underwent lung transplantation in Japan and showed reasonable efficacy. Therefore, public health insurance coverage for inhaled NO therapy during lung transplantation is recommended.
KW - Extracorporeal membrane oxygenation
KW - Health insurance
KW - Lung transplantation
KW - Nitric oxide
KW - Side effect
UR - http://www.scopus.com/inward/record.url?scp=85106223163&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106223163&partnerID=8YFLogxK
U2 - 10.1007/s11748-021-01648-8
DO - 10.1007/s11748-021-01648-8
M3 - Article
C2 - 33999348
AN - SCOPUS:85106223163
SN - 1863-6705
VL - 69
SP - 1421
EP - 1431
JO - General Thoracic and Cardiovascular Surgery
JF - General Thoracic and Cardiovascular Surgery
IS - 10
ER -
